

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



TransThera Sciences (Nanjing), Inc.
藥捷安康（南京）科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2617)

VOLUNTARY ANNOUNCEMENT
INCLUSION OF THE COMPANY AS A CONSTITUENT OF
THE HANG SENG INDEX SERIES

This announcement is made by TransThera Sciences (Nanjing), Inc. (the “**Company**”, together with its subsidiaries collectively referred to as the “**Group**”) on a voluntary basis, the purpose of which is to inform the shareholders and potential investors of the Company of the latest development of the Company.

The board of directors (the “**Board**”) of the Company is pleased to announce that, pursuant to the quarterly review results of the Hang Seng Index Series published by Hang Seng Indexes Company Limited on August 22, 2025, the Company has been selected and will be included as a constituent of the Hang Seng Index Series, including but not limited to the following, with effect from September 8, 2025:

1. Hang Seng Composite Index;
2. Hang Seng Composite Industry Index – Healthcare;
3. Hang Seng Composite MidCap & SmallCap Index;
4. Hang Seng Composite SmallCap Index;
5. Hang Seng Healthcare Index;
6. Hang Seng Innovative Drug Index;
7. Hang Seng SCHK Innovative Drug Index;
8. Hang Seng SCHK Innovative Drug Select Index; and
9. Hang Seng SCHK Pharmaceuticals & Biotechnology (Investable) Index.

The Board believes that the Company's inclusion in the Hang Seng Composite Index and the aforementioned indices reflects growing recognition from investors.

By Order of the Board
TransThera Sciences (Nanjing), Inc.
藥捷安康(南京)科技股份有限公司
Dr. Frank Wu
Chairman and Chief Executive Officer

Hong Kong, August 25, 2025

As at the date of this announcement, the Board comprises Dr. Frank Wu and Mr. Wu Di as executive Directors; Ms. Jia Zhongxin and Dr. Yi Hua as non-executive Directors; and Ms. Chui Hoi Yam, Ms. Zheng Zhelan and Mr. Li Shu Pai as independent non-executive Directors.